The efficacy and safety of ciprofol use for the induction of general anesthesia in patients undergoing gynecological surgery: a prospective randomized controlled study

Ben-Zhen Chen, Xin-Yu Yin, Li-Hua Jiang, Jin-Hui Liu, Yan-Yan Shi, Bi-Ying Yuan, Ben-Zhen Chen, Xin-Yu Yin, Li-Hua Jiang, Jin-Hui Liu, Yan-Yan Shi, Bi-Ying Yuan

Abstract

Background: Ciprofol is a recently developed, short-acting γ-aminobutyric acid receptor agonist sedative that is more potent than propofol, but there have been few clinical studies of this agent to date. Here, we sought to examine the safety and efficacy of ciprofol use for the induction of general anesthesia in individuals undergoing gynecological surgery.

Methods: Women between the ages of 18 and 60 years (ASA physical status 1 or 2) who were scheduled to undergo elective gynecological surgery under general anesthesia were randomly assigned to two equally sized groups in which anesthesia induction was performed using either ciprofol or propofol. General anesthesia induction success rates were the primary outcome for this study, while secondary outcomes included changes in BIS during the 10 min following the first administration of the study drug, the duration of successful induction, and adverse event incidence.

Results: A total of 120 women were included in the study. A 100% rate of successful induction was achieved in both the ciprofol and propofol groups, with no significant differences between these groups with respect to the duration of successful induction (34.8 ± 15.5 s vs 35.4 ± 9.5 s, P = 0.832), the time to the disappearance of the eyelash reflex (33.7 ± 10.6 s vs 34.0 ± 6.5 s, P = 0.860), or tracheal intubation (58.2 ± 31.1 s vs 53.9 ± 25.4 s, P = 0.448). Adverse event rates, including intubation responses, were significantly lower in the ciprofol group as compared to the propofol group(20% vs 48.33%, P = 0.0019). Ciprofol was associated with reduced injection pain relative to propofol (16.7% vs 58.3%, P < 0.001).

Conclusions: Ciprofol exhibits comparable efficacy to that of propofol when used for the induction of general anesthesia in individuals undergoing gynecological surgery and is associated with fewer adverse events.

Keywords: Ciprofol; General anesthesia; Gynecological surgery; Induction.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT Flow Diagram
Fig. 2
Fig. 2
Changes in blood pressure and heart rate following anesthesia induction; Time 0 was defined as the baseline value 10 s prior to the administration of the study drug; #: P < 0.01
Fig. 3
Fig. 3
Changes in the bispectral index (BIS) following anesthesia induction; Time 0 was defined as the baseline value 10 s prior to the administration of the study drug; #: P < 0.01

References

    1. Sahinovic MM, Struys M, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57:1539–1558. doi: 10.1007/s40262-018-0672-3.
    1. Mirenda J, Broyles G. Propofol as used for sedation in the ICU. Chest. 1995;108:539–548. doi: 10.1378/chest.108.2.539.
    1. Kanaya N, Gable B, Wickley PJ, et al. Experimental conditions are important determinants of cardiac inotropic effects of propofol. Anesthesiology. 2005;103:1026–1034. doi: 10.1097/00000542-200511000-00017.
    1. McWilliams K, Keeley PW, Waterhouse ET. Propofol for terminal sedation in palliative care: a systematic review. J Palliat Med. 2010;13:73e76. doi: 10.1089/jpm.2009.0126.
    1. Coté GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-related complications with propofol use during advanced endoscopic procedures. Clin Gastroenterol Hepatol. 2010;8:137–142. doi: 10.1016/j.cgh.2009.07.008.
    1. Marik PE. Propofol: therapeutic indications and side effects. Curr Pharm Des. 2004;10:3639–3649. doi: 10.2174/1381612043382846.
    1. Klement W, Arndt JO. Pain on injection of propofol: effects of concentration and diluent. Br J Anaesth. 1991;67:281–284. doi: 10.1093/bja/67.3.281.
    1. Qin L, Ren L, Wan S, et al. Design, synthesis, and evaluation of novel 2,6-disubstituted phenol derivatives as general anesthetics. J Med Chem. 2017;60:3606–3617. doi: 10.1021/acs.jmedchem.7b00254.
    1. Bian Y, Zhang H, Ma S, et al. Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol. 2021;87(1):93. doi: 10.1111/bcp.14363.
    1. Li X, Yang D, Li Q, et al. Safety, pharmacokinetics, and pharmacodynamics of a single bolus of the γ-aminobutyric acid (GABA) receptor potentiator HSK3486 in healthy Chinese elderly and non-elderly. Front Pharmacol. 2021;12:1–11. doi: 10.3389/fphar.2021.735700.
    1. Kasuya Y, Govinda R, Rauch S, et al. The correlation between bispectral index and observational sedation scale in volunteers sedated with dexmedetomidine and propofol. Anesth Analg. 2009;109(6):1811–1815. doi: 10.1213/ANE.0b013e3181c04e58.
    1. Kim KM, Seo KH, Lee JM, et al. Target-controlled infusion of dexmedetomidine effect-site concentration for sedation in patients undergoing spinal anaesthesia. J Clin Pharm Ther. 2020;45:347–353. doi: 10.1111/jcpt.13085.
    1. Kim TK, Niklewksi PJ, Marin JF, et al. Enhancing a sedation score to include truly noxious stimulation: the Extended Observer’s Assessment of Alertness and Sedation (EOAA/S) Br J Anaesth. 2015;115:569–577. doi: 10.1093/bja/aev306.
    1. Teng Y, Ou M, Wang X, et al. Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: phase IIa and IIb multi-center clinical trials. Eur J Pharm Sci. 2021;164:105904. doi: 10.1016/j.ejps.2021.105904.
    1. Sun L, Ma W, Gao W, et al. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis. 2019;10:542. doi: 10.1038/s41419-019-1761-4.
    1. Mangar D, Holak EJ. Tourniquet at 50 mm Hg followed by intravenous lidocaine diminishes hand pain associated with propofol injection. Anesth Analg. 1992;74:250–252. doi: 10.1213/00000539-199202000-00014.
    1. Valtonen M, et al. Propofol as an induction agent in children: pain on injection and pharmacokinetics. Acta Anaesthesiol Scand. 1989;33:152–155. doi: 10.1111/j.1399-6576.1989.tb02879.x.
    1. Tan CH, Onsiong MK. Pain on injection of propofol. Anaesthesia. 1998;53:468–476. doi: 10.1046/j.1365-2044.1998.00405.x.
    1. Jalota L, Kalira V, George E, et al. Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ. 2011;342:d1110. doi: 10.1136/bmj.d1110.
    1. Doenicke AW, Roizen MF, Rau J, et al. Reducing pain during propofol injection: the role of the solvent. Anesth Analg. 1996;82(3):472–474. doi: 10.1097/00000539-199603000-00007.
    1. Mclntosh MP, Rajewski RA. Comparative canine pharmacokinetics-pharmacodynamics of fospropofol disodium injection, propofol emulsion, and cyclodextrin-enabled propofol solution following bolus parenteral administration. J Pharm Sci. 2012;101:3547–3552. doi: 10.1002/jps.23195.
    1. Moore GD, Walker AM, MacLaren R. Fospropofol: a new sedative-hypnotic agent for monitored anesthesia care. Ann Pharmacother. 2009;43(11):1802–1808. doi: 10.1345/aph.1M290.
    1. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103(4):860–876. doi: 10.1097/00000542-200510000-00026.

Source: PubMed

3
S'abonner